Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour Forced Expiratory Volume After 1 Second (FEV1)-time Profiles of BI 1744 CL 5microg and 10microg (Oral Inhalation, Delivered by the Respimat Inhaler) and Tiotropium Bromide 18microg (Oral Inhalation, Delivered by the HandiHaler) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour Forced Expiratory Volume After 1 Second (FEV1)-time Profiles of BI 1744 CL 5microg and 10microg (Oral Inhalation, Delivered by the Respimat Inhaler) and Tiotropium Bromide 18microg (Oral Inhalation, Delivered by the HandiHaler) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2014

At a glance

  • Drugs Olodaterol (Primary) ; Corticosteroids; Tiotropium bromide; Xanthines
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 09 Sep 2013 Primary endpoint 'AUC-FEV1' has been met.
    • 09 Sep 2013 Results were presented at the European Respiratory Society (ERS) Annual Congress 2013, and were reported in a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top